Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

Cluster analysis and display of genome-wide expression patterns

Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Untangling the ErbB signalling network

Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974

Tissue microarrays for high-throughput molecular profiling of tumor specimens

Kononen, J., Bubendorf, L., Kallionimeni, A., Barlund, M. T., Schraml, P., Leighton, S. B., Torhorst, J. K. H., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,101

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379

Epidermal growth factor-related peptides and their receptors in human malignancies

Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,695

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605

Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice

Zerbe, L. K., Dwyer‐Nield, L. D., Fritz, J. M., Redente, E. F., Shroyer, R. J., Conklin, E., Kane, S., Tucker, C., Eckhardt, S. G., Gustafson, D. L., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0644-z · Cited by 36

Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status

Planck, M., Edlund, K., Botling, J., Micke, P., Isaksson, S., & Staaf, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078614 · Cited by 36

Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer

AHMED, S. M., & Salgia, R. (2006) · Respirology · doi:10.1111/j.1440-1843.2006.00887.x · Cited by 36

Therapeutic and prognostic importance of epithelial–mesenchymal transition in liver cancers: Insights from experimental models

Ogunwobi, O. O., & Liu, C. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.11.007 · Cited by 36

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer

Smith, D. L., Acquaviva, J., Sequeira, M., Jimenez, J.-P., Zhang, C., Sang, J., Bates, R. C., & Proia, D. A. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0329-6 · Cited by 35

3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors

Onion, D., Argent, R. H., Reece-Smith, A. M., Craze, M. L., Pineda, R. G., Clarke, P. A., Ratan, H. L., Parsons, S. L., Lobo, D. N., Duffy, J. P., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0598 · Cited by 35

Re-evaluating the role of epithelial-mesenchymal-transition in cancer progression

Sulaiman, A., Zemin, Y., & Wang, L. (2017) · Journal of Biomedical Research · doi:10.7555/jbr.31.20160124 · Cited by 36

N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells.

Yamauchi, M., Yoshino, I., Yamaguchi, R., Shimamura, T., Nagasaki, M., Imoto, S., Niida, A., Koizumi, F., Kohno, T., Yokota, J., et al. (2011) · Europe PMC (PubMed Central) · Cited by 35

Lung Cancer Genomic Signatures

Agulló-Ortuño, M. T., López‐Ríos, F., & Paz-Ares, L. G. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f1900e · Cited by 33

TGFβ1 rapidly activates Src through a non-canonical redox signaling mechanism

Zhang, H., Davies, K. J. A., & Forman, H. J. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.01.001 · Cited by 33

Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells

Huang, D., Su, L., Peng, X.-H., Zhang, H., Khuri, F. R., Shin, D. M., & Chen, Z. (2009) · Nanotechnology · doi:10.1088/0957-4484/20/22/225102 · Cited by 33

Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents

Fleming, I. N., Hogben, M., Frame, S., McClue, S. J., & Green, S. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4633 · Cited by 33

Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation

Zhao, B.-X., Wang, J., Song, B., WEI, H., Lv, W., TIAN, L.-M., Li, M., & Lv, S. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.3058 · Cited by 32

Downregulation of miR-506-3p Facilitates EGFR-TKI Resistance through Induction of Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines

Haque, I., Kawsar, H. I., Motes, H. C., Sharma, M., Banerjee, S., Banerjee, S. K., Godwin, A. K., & Huang, C. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239307 · Cited by 32

Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma

Kobayashi, M., Miki, Y., Ebina, M., Abe, K., Mori, K., Narumi, S., Suzuki, T., Sato, I., Maemondo, M., Endo, C., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.422 · Cited by 32

Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer

Adams, R., & Maughan, T. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.4.503 · Cited by 32

Multi-omics analysis reveals that ornithine decarboxylase contributes to erlotinib resistance in pancreatic cancer cells

Jang, W., Choi, B., Song, S.-H., Lee, N., Kim, D. J., Lee, S., & Jeong, C. (2017) · Oncotarget · doi:10.18632/oncotarget.21572 · Cited by 29

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

Demuth, C., Madsen, A. T., Weber, B., Wu, L., Meldgaard, P., & Sørensen, B. S. (2018) · BMC Cancer · doi:10.1186/s12885-018-4108-0 · Cited by 31

Systematic Analysis of Drug Vulnerabilities Conferred by Tumor Suppressor Loss

Ding, H., Zhao, J., Zhang, Y. L., Yu, J., Liu, M., Li, X., Xu, L., Lin, M., Liu, C., He, Z., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.043 · Cited by 28

Association of Divergent Carcinoembryonic Antigen Patterns and Lung Cancer Progression

Kuo, Y., Zheng, M., Huang, M.-F., Miao, C., Yang, L., Huang, T.-W., & Chou, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-59031-1 · Cited by 31

Slug increases sensitivity to tubulin‐binding agents via the downregulation of βIII and βIVa‐tubulin in lung cancer cells

Tamura, D., Arao, T., Nagai, T., Kaneda, H., Aomatsu, K., Fujita, Y., MATSUMOTO, K. Y., Velasco, M. A. D., Kato, H., Hayashi, H., et al. (2013) · Cancer Medicine · doi:10.1002/cam4.68 · Cited by 31

Differential Contribution to Neuroendocrine Tumorigenesis of Parallel Egfr Signaling in Cancer Cells and Pericytes

Nolan-Stevaux, O., Truitt, M. C., Pahler, J., Olson, P., Guinto, C., Lee, D. C., & Hanahan, D. (2010) · Genes & Cancer · doi:10.1177/1947601909358722 · Cited by 31

HSP27 modulates epithelial to mesenchymal transition of lung cancer cells in a Smad-independent manner

Mizutani, H., Okano, T., Minegishi, Y., Matsuda, K., Sudoh, J., Kitamura, K., Noro, R., Soeno, C., Yoshimura, A., Seike, M., et al. (2010) · Oncology Letters · doi:10.3892/ol.2010.190 · Cited by 33

Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor.

Boeckx, C., Blockx, L., de Beeck, K. O., Limame, R., Camp, G. V., Peeters, M., Vermorken, J. B., Specenier, P. M., Wouters, A., Baay, M. F. D., et al. (2015) · Europe PMC (PubMed Central) · Cited by 30

Snail Is a Critical Mediator of Invadosome Formation and Joint Degradation in Arthritis

Lauzier, A., Lavoie, R. R., Charbonneau, M., Gouin-Boisvert, B., Harper, K., & Dubois, C. M. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.10.021 · Cited by 29

Inhibition of AMPK-related kinase 5 (ARK5) enhances cisplatin cytotoxicity in non-small cell lung cancer cells through regulation of epithelial-mesenchymal transition.

Li, M., Zheng, C., Xu, H., He, W., Ruan, Y., Jian-yong, M., Zheng, J., Ye, C., & Li, W. (2017) · PubMed Central · Cited by 29

Hyperglycemia as a mechanism of pancreatic cancer metastasis

Li, W. (2011) · Frontiers in bioscience · doi:10.2741/4017 · Cited by 29

Cooperative Signaling between Oncostatin M, Hepatocyte Growth Factor and Transforming Growth Factor-β Enhances Epithelial to Mesenchymal Transition in Lung and Pancreatic Tumor Models

Argast, G. M., Mercado, P., Mulford, I. J., O’Connor, M., Keane, D. M., Shaaban, S. A., Epstein, D. M., Pachter, J. A., & Kan, J. L. C. (2010) · Cells Tissues Organs · doi:10.1159/000320179 · Cited by 28

Molecular Pathology of Lung Cancer

Solis, L. M., & Wistuba, I. I. (2012) · Springer eBooks · doi:10.1007/978-1-4419-0787-5_14 · Cited by 27

MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells

Maharati, A., Zangouei, A. S., Khalili‐Tanha, G., & Moghbeli, M. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00840-4 · Cited by 28

Odin (ANKS1A) Modulates EGF Receptor Recycling and Stability

Tong, J., Sydorskyy, Y., St-Germain, J. R., Taylor, P., Tsao, M. S., & Moran, M. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064817 · Cited by 25

Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells

Yoshioka, M., Ohashi, S., Ida, T., Nakai, Y., Kikuchi, O., Amanuma, Y., Matsubara, J., Yamada, A., Miyamoto, S., Natsuizaka, M., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0572-7 · Cited by 27

Targeting the growth factors and angiogenesis pathways: Small molecules in solid tumors

Berz, D., & Wanebo, H. J. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21776 · Cited by 26

EGFR Inhibition Promotes an Aggressive Invasion Pattern Mediated by Mesenchymal-like Tumor Cells within Squamous Cell Carcinomas

Basu, D., Bewley, A. F., Sperry, S. M., Montone, K. T., Gimotty, P. A., Räsänen, K., Facompre, N. D., Weinstein, G. S., Nakagawa, H., Diehl, J. A., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1210 · Cited by 26

Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance

Han, R., Jia, Y., Li, X., Zhao, C., Zhao, S., Liu, S., Liu, Y., Chen, D., Zhang, Q., Liu, X., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1153 · Cited by 27

Insulin-like Growth Factor-1 Receptor and ErbB Kinase Inhibitor Combinations Block Proliferation and Induce Apoptosis through Cyclin D1 Reduction and Bax Activation

Wilsbacher, J. L., Zhang, Q., Tucker, L. A., Hubbard, R. D., Sheppard, G. S., BaMaung, N. Y., Fidanze, S. D., Wang, G. T., Hu, X., Davidsen, S. K., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708360200 · Cited by 26

Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition

Kitahara, H., Hirai, M., Kato, K., Bou–Gharios, G., Nakamura, H., & Kawashiri, S. (2016) · Oncology Reports · doi:10.3892/or.2016.5189 · Cited by 26

RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.

Xu, Z., Hang, J., Hu, J., & Gao, B. (2013) · Europe PMC (PubMed Central) · Cited by 25

Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants

Chung, B. M. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i5.806 · Cited by 25

The multiple roles and therapeutic potential of clusterin in non-small-cell lung cancer: a narrative review

Tan, J., Guo, W., Yang, S., Han, D., & Li, H. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1298 · Cited by 25

The importance of matrix metalloproteinase-3 in respiratory disorders

Yamashita, C. M., Radisky, D. C., Aschner, Y., & Downey, G. P. (2014) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2014.909288 · Cited by 26

Epithelial–mesenchymal transition in pulmonary carcinosarcoma: case report and literature review

Thomas, V. T., Hinson, S., & Konduri, K. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011421949 · Cited by 25

Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?

Ulivi, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071186 · Cited by 24

Ecological responses and remediation ability of water fern (Azolla japonica) to water pollution

Song, U., Park, H., & Lee, E. J. (2012) · Journal of Plant Biology · doi:10.1007/s12374-012-0010-5 · Cited by 24

Identification of Transcriptional Subgroups in EGFR -Mutated and EGFR / KRAS Wild-Type Lung Adenocarcinoma Reveals Gene Signatures Associated with Patient Outcome

Planck, M., Isaksson, S., Veerla, S., & Staaf, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0928 · Cited by 24

Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors

Chan, S., Zhang, Y., Wang, J., Yu, Q., Xia, P., Zou, J., Zhou, L., Tan, L., Duan, Y., Zhou, Y., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01346 · Cited by 23

Inhibition of ZNF746 suppresses invasion and epithelial to mesenchymal transition in H460 non-small cell lung cancer cells

Kim, B., Sohn, E. J., Jung, J. H., SHIN, E. A., You, O. H., IM, J., & Kim, S. (2013) · Oncology Reports · doi:10.3892/or.2013.2801 · Cited by 23

High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer

Park, K., Moon, Y. W., Raffeld, M. A., Lee, K. H., Wang, Y., & Giaccone, G. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.12.010 · Cited by 23

Upregulation of EphB3 in gastric cancer with acquired resistance to a FGFR inhibitor

Lee, S., Na, Y. J., Jeong, Y. A., Kim, J. L., Oh, S. C., & Lee, D.-H. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.07.008 · Cited by 23

Poly(ADP-ribose) polymerase-1 regulates vimentin expression in lung cancer cells

Chu, S., Xu, H., Ferro, T. J., & Rivera, P. X. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00197.2007 · Cited by 24

h‐Prune is associated with poor prognosis and epithelial–mesenchymal transition in patients with colorectal liver metastases

Hashimoto, M., Kobayashi, T., Tashiro, H., Arihiro, K., Kikuchi, A., & Ohdan, H. (2016) · International Journal of Cancer · doi:10.1002/ijc.30118 · Cited by 22

Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in EGFR Wild-Type Non–Small Cell Lung Carcinoma Cell Lines

Augustin, A., Lamerz, J., Meistermann, H., Golling, S., Scheiblich, S., Hermann, J. C., Duchâteau-Nguyen, G., Tzouros, M., Avila, D. W., Langen, H., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0880 · Cited by 21

Resistance to targeted cancer drugs through hepatocyte growth factor signaling

Heynen, G. J. J. E., Fonfara, A., & Bernards, R. (2014) · Cell Cycle · doi:10.4161/15384101.2014.988033 · Cited by 21

ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma

Li, J., Ao, J., Li, K., Zhang, J., Li, Y., Zhang, L., Wei, Y., Gong, D., Gao, J., Tan, W., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.328 · Cited by 21

Novel insights into the molecular origins and treatment of lung cancer

Webb, J. D., & Simon, M. C. (2010) · Cell Cycle · doi:10.4161/cc.9.20.13588 · Cited by 21

Current Challenges and Future Directions

Matthews, D., & Gerritsen, M. E. (2010) · Wiley eBooks · doi:10.1002/9780470555293.ch11 · Cited by 21

HPRT promotes proliferation and metastasis in head and neck squamous cell carcinoma through direct interaction with STAT3

Wang, L., Wang, Y., Han, N., Wang, X., & Ruan, M. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112424 · Cited by 20

Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer

Wang, S., Rong, R., Yang, D. M., Fujimoto, J., Bishop, J. A., Yan, S. X., Cai, L., Behrens, C., Berry, L. D., Wilhelm, C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci160330 · Cited by 22

Relationship Between Increased Expression of the Axl/Gas6 Signal Cascade and Prognosis of Patients with Upper Tract Urothelial Carcinoma

Hattori, S., Kikuchi, E., Kosaka, T., Miyazaki, Y. J., Tanaka, N., Miyajima, A., Mikami, S., & Oya, M. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4848-x · Cited by 20

Nutlin-3 inhibits epithelial–mesenchymal transition by interfering with canonical transforming growth factor-β1-Smad-Snail/Slug axis

Wu, Y., Fu, Y., Zheng, L., Lin, G., Ma, J., Lou, J.-S., Zhu, H., He, Q., & Yang, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.039 · Cited by 20

Genetic Clonality as the Hallmark Driving Evolution of Non-Small Cell Lung Cancer

Nicoś, M., & Krawczyk, P. A. (2022) · Cancers · doi:10.3390/cancers14071813 · Cited by 21

Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models

Haley, J. D., Haughney, E., Ullman, E., Bean, J. M., Haley, J. D., & Fink, M. Y. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00344 · Cited by 19

Erlotinib in the first-line treatment of non-small-cell lung cancer

D’Arcangelo, M., & Cappuzzo, F. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.23 · Cited by 19

Transforming growth factor-β1-induced epithelial to mesenchymal transition increases mitochondrial content in the A549 non-small cell lung cancer cell line

Xu, Y., & Lü, S. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2678 · Cited by 18

Role of the Pulmonologist in Ordering Post-Procedure Molecular Markers in Non–Small-Cell Lung Cancer: Implications for Personalized Medicine

Murgu, S. D., & Colt, H. G. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.04.002 · Cited by 17

Synergistic antitumor activity of aspirin and erlotinib: Inhibition of p38 enhanced aspirin plus erlotinib‑induced suppression of metastasis and promoted cancer cell apoptosis

Hu, X., Wu, L., Weng, X., Lin, N., & Zhang, C. (2018) · Oncology Letters · doi:10.3892/ol.2018.8956 · Cited by 17

Clinicopathological features and epidermal growth factor receptor mutations associated with epithelial–mesenchymal transition in non‐small cell lung cancer

Deng, Q., Cai‐Cun, Z. H. O. U., & Su, C. (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01496.x · Cited by 17

From the bench to the bed: individualizing treatment in non-small-cell lung cancer

Santarpía, M., Altavilla, G., Salazar, F., Tarón, M., & Rosell, R. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0161-2 · Cited by 17

Intratumoral budding: A novel prognostic biomarker for tumor recurrence and a potential predictor of nodal metastasis in uterine cervical cancer

Chong, G. O., Park, J. Y., Han, H. S., Cho, J., Kim, M.-G., Choi, Y., Yeo, J. Y., Lee, Y. H., Hong, D. G., & Park, J. Y. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.07.009 · Cited by 16

SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer

Zhou, J., Zhang, X., Xue, S., Dai, M., Wang, Y., Xia, P., Chen, J., Wang, X., Shen, Y., Qin, H., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01403-w · Cited by 16

Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer

Larsson, A. H., Lehn, S., Wangefjord, S., Karnevi, E., Kuteeva, E., Sundström, M., Nodin, B., Uhlén, M., Eberhard, J., Birgisson, H., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0882-0 · Cited by 16

FHITlow / pHER2high signature in non‐small cell lung cancer is predictive of anti‐HER2 molecule efficacy

silva, J. D., Jouida, A., Ancel, J., Dalstein, V., Routhier, J., Delépine, G., Cutrona, J., Jonquet, A., Dewolf, M., Birembaut, P. L., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5439 · Cited by 16

Epithelial–Mesenchymal Transition in Mouse Mammary Tumorigenesis

Radaelli, E., Damonte, P., & Cardiff, R. D. (2009) · Future Oncology · doi:10.2217/fon.09.93 · Cited by 15

Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non–Small-Cell Lung Cancer

Neal, J. W., & Sequist, L. V. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0860 · Cited by 15

Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib

Hülsmann, H., Rolff, J., Bender, C., Jarahian, M., Korf, U., Herwig, R., Fröhlich, H., Thomas, M., Merk, J., Fichtner, I., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.09.001 · Cited by 16

The Role of Epithelial–Mesenchymal Transition and IGF-1R Expression in Prediction of Gefitinib Activity as the Second-Line Treatment for Advanced Nonsmall-Cell Lung Cancer

Chen, B., Xiao, F., Li, B., Xie, B., Zhou, J., Zheng, J., & Zhang, W. (2013) · Cancer Investigation · doi:10.3109/07357907.2013.820315 · Cited by 15

Molecular mechanisms of therapy resistance in solid tumors: chasing “moving” targets

Tafe, L. J. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2101-7 · Cited by 14

Comparative gene co-expression network analysis of epithelial to mesenchymal transition reveals lung cancer progression stages

Wang, D., Haley, J. D., & Thompson, P. A. (2017) · BMC Cancer · doi:10.1186/s12885-017-3832-1 · Cited by 14

NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells

He, L. C., Liu, K., Wang, X., Chen, H., Zhou, J., Wu, X., Liu, T., Yang, Y., Yang, X., Cui, D., et al. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.05.003 · Cited by 14

4-Hydroxynonenal activates Src through a non-canonical pathway that involves EGFR/PTP1B

Zhang, H.-Q., & Forman, H. (2015) · Free Radical Biology & Medicine · doi:10.1016/j.freeradbiomed.2015.08.025 · Cited by 13

Resistance to Therapy

Rivera, G. A., & Wakelee, H. A. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40389-2_9 · Cited by 14

SUMOylation of SMAD4 by PIAS1 in Conjunction with Vimentin Upregulation Promotes Migration Potential in Non-Small Cell Lung Cancer

Wu, C., Zhu, X.-X., Dai, Q., Chu, Z., Yang, S., & Dong, Z. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2808192 · Cited by 13

The gefitinib long-term responder (LTR)—A cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)

Gottschling, S., Herpel, E., Eberhardt, W., Heigener, D. F., Fischer, J. R., Köhne, C., Kortsik, C., Kuhnt, T., Muley, T., Meister, M. A., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.03.003 · Cited by 14

[Epithelial-mesenchymal transition and tumor metastasis].

Zhao, R., Wu, Z., & Zhou, Q. (2011) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2011.07.11 · Cited by 13

Treatment in EGFR-mutated Non-small Cell Lung Cancer: How to Block the Receptor and overcome Resistance Mechanisms

Proto, C., Russo, G. L., Corrao, G., Ganzinelli, M., Facchinetti, F., Minari, R., Tiseo, M., & Garassino, M. C. (2017) · Tumori Journal · doi:10.5301/tj.5000663 · Cited by 14

TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X

Ito, K., Nishio, M., Kato, M., Murakami, H., Aoyagi, Y., Ohe, Y., Okayama, T., Hashimoto, A., Ohsawa, H., Tanaka, G., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0645 · Cited by 12

Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor requires E-cadherin in esophageal cancer and malignant pleural mesothelioma.

Xin, H., Yang, J. H., & Nguyen, D. M. (2013) · PubMed · Cited by 11

Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy

Fidler, M. J., Frankenberger, C. A., Seto, R., Lobato, G. C., Fhied, C. L., Sayidine, S., Basu, S., Pool, M. D., Karmali, R., Batus, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17510 · Cited by 10

Cytokine and epigenetic regulation of CEACAM6 mediates EGFR-driven signaling and drug response in lung adenocarcinoma

Zheng, M., Lin, Y., Kuo, Y., Lin, Y., Kuo, M.-H., Huang, T.-W., Shieh, Y., Huang, Y., & Chou, Y. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00910-z · Cited by 10

Transcription factor glioma-associated oncogene homolog 1 is required for transforming growth factor-β1-induced epithelial-mesenchymal transition of non-small cell lung cancer cells

Li, H., Da, L., Fan, W., Long, X.-H., & Zhang, X. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3150 · Cited by 10

E‐cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models

Bruun, J., Eide, P. W., Bergsland, C. H., Brück, O. E., Svindland, A., Arjama, M., Välimäki, K. E., Bjørnslett, M., Guren, M. G., Kallioniemi, O., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13159 · Cited by 10

Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?

Villaflor, V. M., & Salgia, R. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.109253 · Cited by 10

Erlotinib has tumor inhibitory effect in human retinoblastoma cells

Shao, Y., Yao, Y., Zong, R., Quyang, L., He, H., Zhou, Q., & Pei, C.-G. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.054 · Cited by 10

Decoupling of Nrf2 Expression Promotes Mesenchymal State Maintenance in Non-Small Cell Lung Cancer

Haley, J. D., Ruiz, C. F., Montal, E. D., Wang, D., Haley, J. D., & Girnun, G. D. (2019) · Cancers · doi:10.3390/cancers11101488 · Cited by 10

RB1, Cancer Lineage Plasticity, and Therapeutic Resistance

Zhang, L., & Goodrich, D. W. (2022) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-092840 · Cited by 10

Investigation of role of CpG methylation in some epithelial mesenchymal transition gene in a chemoresistant ovarian cancer cell line

Alghamian, Y., Soukkarieh, C., Abbady, A. Q., & Murad, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-11634-6 · Cited by 9

Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer

Dazio, G., Epistolio, S., Frattini, M., & Saletti, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247523 · Cited by 10

Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers

Alshareef, A. (2017) · Cancers · doi:10.3390/cancers9110148 · Cited by 10

The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro

Wang, J., Wei, H., Zhao, B.-X., Li, M., Lv, W., Lv, L., Song, B., & Lv, S. (2014) · Journal of Molecular Histology · doi:10.1007/s10735-014-9583-2 · Cited by 9

Tumor Microenvironment

Walser, T. C., Yanagawa, J., Garon, E. B., Lee, J. M., & Dubinett, S. M. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-524-8_2 · Cited by 9

Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non–Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition

Thomson, S., Buck, E. A., Petti, F., Griffin, G., Brown, E., Ramnarine, N., Iwata, K. K., Gibson, N. W., & Haley, J. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1058 · Cited by 663

Erlotinib sensitivity in NSCLC cell lines correlates with an epithelial to mesenchymal transition which induces a switch in receptor tyrosine kinase signaling.

Thomson, S., Petti, F., Sujka-Kwok, I., Buck, E. A., Barr, S. M., Miglarese, M. R., & Haley, J. D. (2007) · Molecular Cancer Therapeutics

Abstract 5063: Preclinical evaluation of an EMT multi-gene biomarker index for predicting response to inhibitors of EGFR and IGF1R

Argast, G. M., Bean, J. M., Wang, J., O'Connor, M., Feng, B., Nicoletti, R., Lerner, L. R., Heyer, J., Chiu, M. I., Robinson, M. O., et al. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-5063

Epithelial to mesenchymal markers and clinical outcomes on erlotinib in stage IV non-small cell lung cancer patients.

Pool, M. D., Fidler, M. J., Basu, S., Mahon, B., Buckingham, L. E., Walters, K. K., Batus, M., Hensing, T. A., Borgia, J. A., & Bonomi, P. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.e19117

P3-015: Clinicopathologic features and epidermal growth factor receptor mutations associated with epithelial-mesenchymal transition in non-small cell lung cancer

Zhou, C., Deng, Q., & Su, C. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000283501.96516.b4